Aptorum To Start Testing SACT-1 In Neuroblastoma Patients

  • The FDA has signed off Aptorum Group Limited's APM IND application to initiate clinical trials of SACT-1 for neuroblastoma.
  • The IND-opening trial is a bioavailability/food effect study that will take four months to complete.
  • The bioavailability/food effect study aims to compare the relative bioavailability of the newly developed SACT-1 pediatric formulation in healthy adult subjects.
  • The above study will follow a planned Phase 1b/2a trial in pediatric patients with relapsed or refractory high-risk neuroblastoma. 
  • SACT-1 is an orally administered repurposed small molecule drug designed to suppresses MYCN expression (a protein found in neuroblastoma patients).
  • SACT-1 is designed to be used especially in combination with standard-of-care chemotherapy.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: APM shares are up 2.66% at $2.70 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefsNeuroblastomaPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!